Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 654   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2000  |  Volume : 18  |  Issue : 2  |  Page : 54-58

Multi Drug Resistance In Human Lung Cancer And Its Pharmacological Reversal

Correspondence Address:
Rakesh C Gupta

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Resistance to anti cancer drugs is not so uncommon and often limits the efficacy of given regimen with the consequences of loss of precious time, money and untoward drug reactions. Among the known mechanisms for drug resistance with cytotoxic agents, some are relevant to lung cancer cell lines. These includes reduced drug accumulation as a result of genetic alteration in drug transportation (carrier proteins), enhanced drug inactivation, target enzyme alteration, enhanced DNA repair and apoptosis. Interventions to circumvent resistance are still under evaluation. Use of verapamil to block P-170 glycoprotein, amphotericin-B and dipyridamole to enhance cellular transport of cisplatin, ethacrynic acid to decrease thiotepa inactivation, pentoxyphylline to retard DNA rapair process, ceftriaxone to reduce multidrug resistance and paclitaxel as a biological response modifier are some examples which hold promise for regular clinical utility.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded88    
    Comments [Add]    

Recommend this journal